-
Je něco špatně v tomto záznamu ?
Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control
J. Šoupal, J. Škrha, M. Fajmon, E. Horová, M. Mráz, J. Škrha, M. Prázný,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24401008
DOI
10.1089/dia.2013.0205
Knihovny.cz E-zdroje
- MeSH
- albuminurie MeSH
- ambulantní monitorování metody MeSH
- analýza rozptylu MeSH
- biologické markery krev MeSH
- diabetes mellitus 1. typu krev komplikace patofyziologie MeSH
- diabetické angiopatie krev etiologie patofyziologie MeSH
- dospělí MeSH
- glykovaný hemoglobin metabolismus MeSH
- hodnocení rizik MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- odds ratio MeSH
- prediktivní hodnota testů MeSH
- průřezové studie MeSH
- selfmonitoring glykemie MeSH
- vibrace MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Increased glycemic variability (GV) may be associated with diabetes complications. Our study assessed the relationship between microvascular complications (MVCs) and GV calculated from continuous glucose monitoring (CGM) data in type 1 diabetes patients. SUBJECTS AND METHODS: Thirty-two patients with type 1 diabetes (16 with and 16 without MVC) participated in this cross-sectional study. Vibration perception threshold (VPT), microalbuminuria, and fundoscopy were used to detect MVC. CGM data were recorded for 2 weeks and analyzed using proprietary software. Total SD (SDT), coefficient of variation (CV), and mean amplitude of glycemic excursions (MAGE) were compared. RESULTS: Patients with any MVC had significantly higher GV, calculated from CGM, than patients without MVC (SDT, 4.1 ± 0.6 vs. 3.4 ± 0.8 mmol/L [P = 0.010]; CV, 0.43 ± 0.06 vs. 0.38 ± 0.08 [P = 0.032]; MAGE, 6.9 ± 1.2 vs. 5.9 ± 1.2 mmol/L [P = 0.014]) but comparable glycated hemoglobin (HbA1c) (70 ± 9 vs. 69 ± 10 mmol/mol [8.6 ± 0.8% vs. 8.5 ± 0.9%], difference not significant). No significant difference in GV was found between the two groups when using only self-monitored blood glucose (SMBG) data. A positive association was found between VPT and SDT in all patients (r = 0.51, P = 0.0026). CONCLUSIONS: Patients with type 1 diabetes and any MVC had significantly higher GV calculated from CGM, but not from SMBG, than patients with comparable glycemic control but without complications. This supports the hypothesis that increased GV might be associated with MVC in type 1 diabetes and that HbA1c may not describe diabetes control completely.
3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008414
- 003
- CZ-PrNML
- 005
- 20180516101410.0
- 007
- ta
- 008
- 150306s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/dia.2013.0205 $2 doi
- 035 __
- $a (PubMed)24401008
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šoupal, Jan $7 xx0224300 $u 3rd Department of Internal Medicine, First Faculty of Medicine, Charles University , Prague, Czech Republic .
- 245 10
- $a Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control / $c J. Šoupal, J. Škrha, M. Fajmon, E. Horová, M. Mráz, J. Škrha, M. Prázný,
- 520 9_
- $a BACKGROUND: Increased glycemic variability (GV) may be associated with diabetes complications. Our study assessed the relationship between microvascular complications (MVCs) and GV calculated from continuous glucose monitoring (CGM) data in type 1 diabetes patients. SUBJECTS AND METHODS: Thirty-two patients with type 1 diabetes (16 with and 16 without MVC) participated in this cross-sectional study. Vibration perception threshold (VPT), microalbuminuria, and fundoscopy were used to detect MVC. CGM data were recorded for 2 weeks and analyzed using proprietary software. Total SD (SDT), coefficient of variation (CV), and mean amplitude of glycemic excursions (MAGE) were compared. RESULTS: Patients with any MVC had significantly higher GV, calculated from CGM, than patients without MVC (SDT, 4.1 ± 0.6 vs. 3.4 ± 0.8 mmol/L [P = 0.010]; CV, 0.43 ± 0.06 vs. 0.38 ± 0.08 [P = 0.032]; MAGE, 6.9 ± 1.2 vs. 5.9 ± 1.2 mmol/L [P = 0.014]) but comparable glycated hemoglobin (HbA1c) (70 ± 9 vs. 69 ± 10 mmol/mol [8.6 ± 0.8% vs. 8.5 ± 0.9%], difference not significant). No significant difference in GV was found between the two groups when using only self-monitored blood glucose (SMBG) data. A positive association was found between VPT and SDT in all patients (r = 0.51, P = 0.0026). CONCLUSIONS: Patients with type 1 diabetes and any MVC had significantly higher GV calculated from CGM, but not from SMBG, than patients with comparable glycemic control but without complications. This supports the hypothesis that increased GV might be associated with MVC in type 1 diabetes and that HbA1c may not describe diabetes control completely.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a albuminurie $7 D000419
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a selfmonitoring glykemie $7 D015190
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a diabetes mellitus 1. typu $x krev $x komplikace $x patofyziologie $7 D003922
- 650 _2
- $a diabetické angiopatie $x krev $x etiologie $x patofyziologie $7 D003925
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glykovaný hemoglobin $x metabolismus $7 D006442
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ambulantní monitorování $x metody $7 D018670
- 650 _2
- $a odds ratio $7 D016017
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a vibrace $7 D014732
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Škrha, Jan
- 700 1_
- $a Fajmon, Martin
- 700 1_
- $a Horová, Eva
- 700 1_
- $a Mráz, Miloš
- 700 1_
- $a Škrha, Jan
- 700 1_
- $a Prázný, Martin
- 773 0_
- $w MED00173679 $t Diabetes technology & therapeutics $x 1557-8593 $g Roč. 16, č. 4 (2014), s. 198-203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24401008 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20180516101545 $b ABA008
- 999 __
- $a ok $b bmc $g 1065687 $s 891214
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 16 $c 4 $d 198-203 $i 1557-8593 $m Diabetes technology & therapeutics $n Diabetes Technol Ther $x MED00173679
- LZP __
- $a Pubmed-20150306